Medium reagent Lucica®

preclinicalclinicalliquid

The Lucica® method for Glycated Albumin (GA), manufactured by Asahi Kasei Pharma Corporation, is a specific test for GA that is now FDA cleared for sale in the U.S. The Lucica® test is distributed exclusively by EKF USA (former Stanbio). The Lucica® test is one of the most widely used and published GA methods worldwide. What are the advantages of Glycated Albumin testing? Lucica® Glycated Albumin-L is specific for GA. It does not measure other glycated proteins such as glycated immunoglobulins. Measures both glycated albumin and total albumin in separate reactions. Results are expressed as a ratio, thus minimizing differences in protein concentrations between patients. Is standardized to an established reference (JCCRM611) via JSCC (Japan Society of Clinical Chemistry). Over the last decade, numerous studies have been published utilizing the Lucica® methodology. What is Glycated Albumin (GA)? Albumin is the most abundant extracellular protein in the circulatory system. Albumin is involved primarily with regulation of osmotic pressure and as a carrier protein for hydrophobic molecules in the bloodstream including drugs, bile acids and free fatty acids. Albumin has a half-life (turnover) of approximately 21 days and is very sensitive to ‘glycation’ by glucose and other sugars in the blood. GA differs from traditional fructosamine tests as it measures GA only. In a fructosamine measurement the majority of the signal is due to GA (~66% of serum proteins is albumin). The remaining signal is comprised of other glycated globulins (~34%). There are numerous fructosamine methods available but these methods lack standardization and don’t report results as a ratio.